Healthcare Industry News: sipuleucel-T
News Release - August 31, 2011
Dendreon Appoints John E. Osborn EVP & General Counsel
SEATTLE--(Healthcare Sales & Marketing Network)-- Dendreon Corporation (Nasdaq:DNDN ) today announced the appointment of John E. Osborn as executive vice president, general counsel and corporate secretary, effective August 30.“John’s experience, particularly in commercial biopharmaceutical organizations, will further strengthen our leadership as Dendreon continues to evolve into a leading oncology company,” said Mitchell H. Gold, president and chief executive officer of Dendreon. “We welcome John to the executive management team.”
Earlier in his career, Mr. Osborn served with the U.S. Department of State during the George H.W. Bush administration, clerked for Judge Albert V. Bryan of the U.S. Fourth Circuit Court of Appeals, and practiced corporate law with Hale and Dorr (now Wilmer Cutler Pickering Hale and Dorr). He recently completed a term as a member of the bipartisan United States Advisory Commission on Public Diplomacy, and he also has been a visiting fellow at Oxford and Princeton Universities, an advisor to the international consulting firm McKinsey & Co., a board member of Incept BioSystems, Inc., and a member of the Leadership Council of the Life Sciences Institute at the University of Michigan.
Mr. Osborn is a Phi Beta Kappa graduate of the University of Iowa, and earned a law degree from the University of Virginia and a master’s in international public policy from Johns Hopkins. He has been elected to membership in the American Law Institute and the Council on Foreign Relations.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
Source: Dendreon
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
